A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
Latest Information Update: 24 Oct 2024
At a glance
- Drugs Docetaxel (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Gemcitabine (Primary) ; BCG; BCG
- Indications Bladder cancer
- Focus Therapeutic Use
- Acronyms BRIDGE
Most Recent Events
- 12 Jan 2023 Status changed from not yet recruiting to recruiting.
- 14 Nov 2022 Planned initiation date changed from 1 Oct 2022 to 1 Nov 2022.
- 19 Sep 2022 New trial record